This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: Gongwin Biopharm Co., Ltd, Gongwin Biopharm Co., Ltd. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2026
Title: Innovations by Nan-Shan Zhong
Introduction
Nan-Shan Zhong is a prominent inventor based in Guangzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of various tumors. With a total of 4 patents to his name, Zhong's work is recognized for its innovative approaches to medical treatment.
Latest Patents
Zhong's latest patents include a method for treating peripheral nerve sheath tumors. This patent describes a pharmaceutical composition that includes a benzenesulfonamide derivative and a pharmaceutically acceptable carrier. The method also outlines a treatment for canine malignant peripheral nerve sheath tumors by administering this composition to affected subjects. Another notable patent focuses on melanoma treatment, which also utilizes a benzenesulfonamide derivative in its formulation. This composition is designed to be administered to subjects in need of melanoma treatment, and it includes provisions for its use in the manufacture of a medicament.
Career Highlights
Zhong is currently associated with Gongwin Biopharm Co., Ltd., where he continues to develop innovative pharmaceutical solutions. His work has garnered attention for its potential impact on cancer treatment, showcasing his dedication to advancing medical science.
Collaborations
Zhong collaborates with esteemed colleagues such as Chuan-Ching Yang and Mao-Yuan Lin, contributing to a dynamic research environment that fosters innovation.
Conclusion
Nan-Shan Zhong's contributions to the field of pharmaceuticals, particularly through his patents, highlight his role as a key innovator in medical treatments. His work continues to pave the way for advancements in cancer therapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile